NewAmsterdam Pharma Co Regulatory Approval
NewAmsterdam Pharma and its partner Menarini Group received European Commission marketing authorization for Ubeslo (obicetrapib) and Evlarco (obicetrapib/ezetimibe FDC) for the treatment of hypercholesterolaemia, marking the first regulatory approval for obicetrapib worldwide. The approval triggers milestone payments to NewAmsterdam in the mid-teens of millions of euros under its existing licensing agreement with Menarini. The company remains eligible for up to €833 million in total milestones plus tiered double-digit royalties on net sales in Europe.
- Counterparty
- Menarini Group